Additional Information

Description

Fosaprepitant 150 mg SDV (Single-Dose Vial) is a medication utilized for the prevention of chemotherapy-induced nausea and vomiting (CINV). As a prodrug of aprepitant, Fosaprepitant is converted to its active form in the body, providing effective antagonism of substance P/neurokinin 1 (NK1) receptors in the brain. This mechanism of action helps to mitigate nausea and vomiting associated with highly emetogenic chemotherapy regimens.

Each vial of Fosaprepitant contains 150 mg of the active ingredient, formulated for intravenous administration. The single-dose vial format facilitates ease of use and ensures precise dosing. The medication is typically administered as a single intravenous infusion prior to the initiation of chemotherapy, aligning with standard protocols for optimal efficacy.

Fosaprepitant’s effectiveness in preventing CINV is supported by clinical studies demonstrating its ability to significantly reduce the incidence of both acute and delayed nausea and vomiting. By targeting the NK1 receptors, it complements other antiemetic agents such as 5-HT3 receptor antagonists and corticosteroids, enhancing overall control of chemotherapy-induced symptoms.

The product is provided in a sterile, single-use vial, ensuring safety and preventing contamination. Fosaprepitant 150 mg SDV is an integral component of a comprehensive antiemetic regimen, contributing to improved patient comfort and compliance during cancer treatment.